Merck
Presence
Merck is one of the...
- Forbes Global 2000 (#73);
- Fortune 500 (#69);
- Global Fortune 500 (#230);
- Russell 3000;
- S&P 500;
- Stoxx 600.
Merck is a company listed under the stock ticker MRK (US).
Merck has a direct presence in 30 countries.Merck has 39 subsidiaries including Merck Animal Health, Merck Cardiovascular and Merck Human Health.
They are in:
- Pharmaceuticals85%
- Biotechnology15%
Acquisition, funding and merger involving Merck.
- Merck has announced the acquisition of Prometheus Biosciences (posted on April 19 2023).
- Merck has announced the acquisition of Imago BioSciences (posted on January 11 2023).
- Merck has announced the acquisition of Imago BioSciences (posted on November 23 2022).
- Merck has announced the acquisition of Seagen (posted on July 7 2022).
- Merck has announced the acquisition of Acceleron Pharma (posted on September 30 2021).
Executives
View the org chart displaying its 214 main executives
Most searched biographies at Merck
- Robert Davis, Chief Executive Officer and Chairman of the Board
- Mary Ellen Coe, Director
- Stephen Mayo, Director
Create your alert
to follow the executive moves at Merck.
Pharmaceuticals
Merck has 1,883 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland).
Popular M&A news in Pharmaceuticals
- Generate Biomedicines has just announced a $273 Million fundraising (posted on September 19 2023).
- Harmony Biosciences has announced the acquisition of Zynerba Pharmaceuticals (posted on August 15 2023).
- Biogen has announced the acquisition of Reata Pharmaceuticals (posted on August 1 2023).
Popular contacts in Pharmaceuticals
News
Press releases by Merck
- Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference - Merck.com
- Merck to Acquire OncoImmune - Merck.com
- Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency - Merck.com
- Merck Announces First-Quarter 2021 Dividend - Merck.com
- Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 - Merck.com
- FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10) - Merck.com
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients… - Me
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue... - Merck.co
- Merck to Acquire VelosBio - Merck.com
- LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer - Merck.com
- View more press releases Close
Social media about Merck
- Merck on Wikipedia, Google News & Yahoo Finance
- Merck on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Thomas Glocer 
